Eikon Therapeutics is a biopharmaceutical company that develops live-cell resolution microscopy and engineering for drug discovery.
Eikon Therapeutics has raised $350.7M in total funding. The most recent round was Series D. The last funding was announced in February 2025.
Eikon Therapeutics's investors include General Catalyst, Lux Capital, Schroders Capital, Foresite Capital, StepStone Group.
Eikon Therapeutics is headquartered in Hayward, United States.
Eikon Therapeutics is a biopharmaceutical company that develops live-cell resolution microscopy and engineering for drug discovery.
Eikon Therapeutics is at the Series D stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Eikon Therapeutics — Funding & Investors." VCBacked, February 26, 2025, https://www.vcbacked.co/company/eikon-therapeutics. Accessed July 19, 2026.
VCBacked. (2025). Eikon Therapeutics — Funding & Investors. Retrieved July 19, 2026, from https://www.vcbacked.co/company/eikon-therapeutics
{{cite web |title=Eikon Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/eikon-therapeutics |website=VCBacked |access-date=July 19, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated